{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:06Z","timestamp":1750538406884,"version":"3.41.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Statin-associated muscle symptoms are a frequent adverse effect of statin treatment and can lead to a statin-associated myopathy characterized by a significant serum creatine kinase increase. We report the case of an 80-year-old man who presented an increased muscular <jats:sup>18<\/jats:sup>F-FDG uptake in a statin-associated muscle symptom without creatine kinase abnormality or inflammation. Statin treatment was discontinued for 6 hours, 3 days, and 7 days on consecutive follow-up examinations. The 1-week window clearly enhanced image quality. This case illustrates the possibility of diffuse muscular <jats:sup>18<\/jats:sup>F-FDG uptake without myositis and the need for a minimal 1-week statin discontinuation to reduce muscular uptake.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004389","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T04:00:46Z","timestamp":1663732846000},"page":"1116-1117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["18F-FDG Muscular Uptake in Statin-Associated Symptoms Without Myositis"],"prefix":"10.1097","volume":"47","author":[{"given":"Gilles","family":"Metrard","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, CHR Orleans, Orleans"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Besse","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, CHR Orleans, Orleans"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelien","family":"Callaud","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, CHR Orleans, Orleans"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederique","family":"Thibault","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, CHR Orleans, Orleans"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14740338.2020.1747431","article-title":"An overview of statin-induced myopathy and perspectives for the future","volume":"19","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1179\/2295333714Y.0000000085","article-title":"Statin-induced rhabdomyolysis mimicking polymyositis on (18)F-FDG PET imaging","volume":"70","year":"2015","journal-title":"Acta Clin Belg"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.crad.2007.04.010","article-title":"Findings on (18)FDG-PET imaging in statin-induced rhabdomyolysis","volume":"62","year":"2007","journal-title":"Clin Radiol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"e006763","DOI":"10.1136\/bmjopen-2014-006763","article-title":"Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation","volume":"5","year":"2015","journal-title":"BMJ Open"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1007\/s00259-020-04775-1","article-title":"(18)F-FDG muscular superscan associated with lipid storage myopathy","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s10067-017-3794-3","article-title":"Multiple values of (18)F-FDG PET\/CT in idiopathic inflammatory myopathy","volume":"36","year":"2017","journal-title":"Clin Rheumatol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.nucmedbio.2012.10.014","article-title":"Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET\/CT","volume":"40","year":"2013","journal-title":"Nucl Med Biol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vph.2014.11.005","article-title":"Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients","volume":"67-69","year":"2015","journal-title":"Vascul Pharmacol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/ard.2010.142455","article-title":"Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study","volume":"70","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1093\/eurheartj\/ehz458","article-title":"Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France","volume":"40","year":"2019","journal-title":"Eur Heart J"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"e2113186","DOI":"10.1001\/jamanetworkopen.2021.13186","article-title":"Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy","volume":"4","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:05:21Z","timestamp":1750536321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004389"}},"subtitle":["How Long to Stop Treatment for Image Quality Improvement?"],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004389","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}